MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma
Launched by ASTRAZENECA · Oct 18, 2023
Trial Information
Current as of August 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new treatment for patients with unresectable pleural mesothelioma, a type of cancer that affects the lining of the lungs and cannot be removed with surgery. Researchers want to see how well a combination of a new drug called Volrustomig (MEDI5752) along with two chemotherapy drugs, Carboplatin and Pemetrexed, works compared to other standard treatments. This is a Phase 3 trial, meaning it is one of the final steps in testing the treatment's effectiveness and safety before it can be approved for general use.
To participate in this trial, you need to be at least 18 years old and have a confirmed diagnosis of pleural mesothelioma that cannot be surgically removed. Other requirements include having measurable disease and being in good overall health, as assessed by your doctor. If you join the trial, you will receive either the new treatment combination or one of the standard treatments chosen by your doctor. This trial is currently recruiting participants, and it is important to discuss with your healthcare team if this study might be right for you.
Gender
ALL
Eligibility criteria
- Key Inclusion Criteria:
- • Participant must be ≥ 18 years at the time of screening
- • Histologically proven diagnosis of pleural mesothelioma with known histology (epithelioid vs. non-epithelioid)
- • Advanced unresectable disease that cannot be treated with curative surgery (with or without chemotherapy)
- • WHO/ECOG performance status of 0 or 1 with no deterioration (that is, ECOG PS\>1) over the previous 2 weeks prior to day of first dosing
- • Has measurable disease per modified RECIST1.1
- • Has adequate bone marrow reserve and organ function at baseline
- Key Exclusion Criteria:
- • As judged by the investigator, any condition that would interfere with evaluation of the investigational product or interpretation of participant safety or study results.
- • Active or prior documented autoimmune or inflammatory disorders
- • History of another primary malignancy with exceptions.
- • Uncontrolled intercurrent illness
- • Tuberculosis, hepatitis B (HBV) or hepatitis C (HCV), human immunodeficiency virus (HIV) infection that is not well controlled
- • Any concurrent chemotherapy, radiotherapy, investigational, biologic, or hormonal therapy for cancer treatment
- • Untreated or progressive CNS metastatic disease
About Astrazeneca
AstraZeneca is a global biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative medicines across various therapeutic areas, including oncology, cardiovascular, respiratory, and autoimmune diseases. With a strong commitment to scientific research and patient-centric solutions, AstraZeneca leverages cutting-edge technology and a robust pipeline to address unmet medical needs. The company collaborates with healthcare professionals, academic institutions, and other organizations to advance clinical trials and deliver transformative therapies, aiming to improve health outcomes and enhance the quality of life for patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Rochester, Minnesota, United States
Houston, Texas, United States
Cleveland, Ohio, United States
Fairfax, Virginia, United States
Valhalla, New York, United States
Gent, , Belgium
Hasselt, , Belgium
Barretos, , Brazil
Porto Alegre, , Brazil
Varese, , Italy
Oviedo, , Spain
Aurora, Colorado, United States
Portland, Oregon, United States
Atlanta, Georgia, United States
Chicago, Illinois, United States
Columbus, Ohio, United States
Kiel, , Germany
Cleveland, Ohio, United States
Portland, Oregon, United States
Leuven, , Belgium
Edmonton, Alberta, Canada
Padova, , Italy
Warszawa, , Poland
Madrid, , Spain
Antwerpen, , Belgium
Philadelphia, Pennsylvania, United States
Lille, , France
Strasbourg, , France
Toulouse, , France
Essen, , Germany
Bari, , Italy
Rotterdam, , Netherlands
Basel, , Switzerland
Bydgoszcz, , Poland
Saint Louis, Missouri, United States
Hamilton, Ontario, Canada
Saint Herblain, , France
St. Gallen, , Switzerland
Leeds, , United Kingdom
Orbassano, , Italy
Atlanta, Georgia, United States
Duarte, California, United States
Bochum, , Germany
Lørenskog, , Norway
Middlesborough, , United Kingdom
Melbourne, , Australia
Cambridge, , United Kingdom
Leicester, , United Kingdom
London, , United Kingdom
Ottawa, Ontario, Canada
Taichung, , Taiwan
Berlin, , Germany
Heidelberg, , Germany
Barcelona, , Spain
Jacksonville, Florida, United States
Sint Niklaas, , Belgium
Regensburg, , Germany
Santa Rosa, California, United States
São Paulo, , Brazil
Beijing, , China
Chongqing, , China
Shanghai, , China
Grosshansdorf, , Germany
Olsztyn, , Poland
Baltimore, Maryland, United States
Rozzano, , Italy
Bern, , Switzerland
Commack, New York, United States
London, Ontario, Canada
Kitakyushu Shi, , Japan
Taipei, , Taiwan
Parma, , Italy
Pretoria, , South Africa
Manchester, , United Kingdom
Portsmouth, , United Kingdom
Milan, , Italy
Monza, , Italy
Matsuyama Shi, , Japan
Clayton, , Australia
Parktown, , South Africa
Kaohsiung, , Taiwan
Tokyo, , Japan
Shandong, , China
Alessandria, , Italy
Montpellier, , France
Changchun, , China
Chengdu, , China
Kunming, , China
Taiyuan, , China
Xi'an, , China
Lyon, , France
Hamburg, , Germany
Guangzhou, , China
Nishinomiya Shi, , Japan
Cape Town, , South Africa
Seoul, , Korea, Republic Of
Gauting, , Germany
Copenhagen, , Denmark
Kraaifontein, , South Africa
Phoenix, Arizona, United States
Rouen, , France
Montréal, Quebec, Canada
Quebec, , Canada
Nanchang, , China
Cheongju Si, , Korea, Republic Of
Changsha, , China
Qingdao, , China
Sao Paulo, , Brazil
Aarhus N, , Denmark
Middlesbrough, , United Kingdom
Brest, , France
Nedlands, , Australia
Chermside, , Australia
Le Mans Cedex, , France
Bergamo, , Italy
Eindhoven, , Netherlands
Hangzhou, , China
Wuhan, , China
Zhengzhou, , China
Kitaadachi Gun, , Japan
Taoyuan, , Taiwan
Ankara, , Turkey
Izmir, , Turkey
East Brunswick, New Jersey, United States
Paris, , France
Bern, , Switzerland
Creteil Cedex, , France
Anderlecht, , Belgium
Tainan City, , Taiwan
Ube Shi, , Japan
Tianjin, , China
Ulsan, , Korea, Republic Of
Westmead, , Australia
Rzeszów, , Poland
Amanzimtoti, , South Africa
Hiroshima Shi, , Japan
Okayama Shi, , Japan
Poznań, , Poland
Harbin, , China
Barakaldo, , Spain
Toronto, Ontario, Canada
Osakasayama Shi, , Japan
Newcastle Upon Tyne, , United Kingdom
Köln, , Germany
Nagoya Shi, , Japan
Santo Andre, , Brazil
Montreal, Quebec, Canada
Lanzhou, , China
Taunton, , United Kingdom
Paris Cedex 18, , France
Fortaleza, , Brazil
Johannesburg, , South Africa
Amagasaki Shi, , Japan
Essen, , Germany
Marseille Cedex 20, , France
Diyarbakir, , Turkey
Adana, , Turkey
Georgsmarienhuette, , Germany
Oslo, , Norway
Fribourg, , Switzerland
Shenyang, , China
Ningbo, , China
Amsterdam, , Netherlands
Rio De Janeiro, , Brazil
Santa Rosa, California, United States
Montreal, Quebec, Canada
Bystra, , Poland
Taiyuan, , China
Joao Pessoa, , Brazil
Münster, , Germany
Cambridge, , United Kingdom
Baden, , Switzerland
Independence, Ohio, United States
Muenster, , Germany
Cardiff, Wales, , United Kingdom
Saint Louis, Missouri, United States
Polokwane, , South Africa
Kimberly, , South Africa
Tianjin, , China
Hakodate Shi, , Japan
Patients applied
Trial Officials
Marjorie G Zauderer, MD
Principal Investigator
Memorial Slone Kettering (MSK) Cancer Centre
Arnaud Scherpereel, MD
Principal Investigator
Lille University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported